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Abstract
Background: Preparations from anthroposophical medicine (AM) are clinically used to treat inflammatory disorders.
We wanted to investigate effects of a selection of AM medications for parenteral use in cell-based systems in vitro.
Methods: Colchicum officinale tuber D3, Mandragora D3, Rosmarinus officinale 5 % and Bryophyllum 5 % were
selected for the experiments. Induction of apoptosis and necrosis (human lymphocytes and dendritic cells [DCs])
and proliferation of lymphocytes as well as maturation (expression of CD14, CD83 and CD86) and cytokine
secretion (IL-10, IL12p70) of DCs were analyzed. Furthermore, proliferation of allogeneic human T lymphocytes was
investigated in vitro in coculture experiments using mature DCs in comparison to controls.
Results: The respective preparations did not induce apoptosis or necrosis in lymphocytes or DCs. Lymphocyte
proliferation was dose-dependently reduced by Colchicum officinale tuber D3 while the viability was unchanged.
Rosmarinus officinale 5 %, but not the other preparations, dose-dependently inhibited the maturation of immature
DCs, reduced secretion of IL-10 and IL-12p70 and slightly inhibited proliferation of allogeneic CD4+ T-lymphocytes
in coculture experiments with DCs.
Conclusion: The selected preparations from AM for parenteral use are nontoxic to lymphocytes and DCs.
Rosmarinus officinale 5 % has immunosuppressive properties on key functions of the immune system which
propose further investigation.
Keywords: Inflammation, Rheumatoid arthritis, Bryophyllum, Kalanchoe pinnata, Colchicum officinale, Mandragora
officinale, Rosmarinus officinale, lymphocytes, dendritic cells
Background
Anthroposophical medicine (AM) is a whole medical
system comprising, among others, art therapies, move-
ment therapies (therapeutic eurythmy) and over 2,000
different medications [1, 2] based on natural substances
(minerals, plants, animals) in homeopathic dilution or as
undiluted extracts. Most of these drugs used in AM are
officially registered in Germany and Switzerland and are
available for clinical use in most European countries.
Hundreds of these drugs are manufactured in ampoules
and approved for parenteral (subcutaneous and/or intra-
venous) use. They are clinically applied for the treatment
of various diseases. In our outpatient center, which is vis-
ited by approximately 2,000 patients per year, we have
seen good outcomes in patients with inflammatory dis-
eases during treatment with AM parenteralia. We were
therefore interested in knowing whether parenterally ap-
plied medications from AM which are used to treat in-
flammatory related disorders like rheumatoid arthritis,
gout or diabetes [3] have immunomodulatory properties
on healthy immunocompetent cells in vitro.
From the over 2,000 different medications of AM listed
in [1, 2], we randomly selected four which fulfilled all of
the three following criteria: I.) availability for parenteral
use, II.) availability in substantial concentrations i.e. not
homoeopathically diluted > D3 (1:1000) and III.) having
documented use for treatment of inflammatory disorders.
Based on these criteria, we selected the highest
* Correspondence: carsten.gruendemann@uniklinik-freiburg.de
Center for Complementary Medicine, Institute for Environmental Health
Sciences, University Medical Center Freiburg, Breisacher Str. 115B, 79106
Freiburg, Germany
© 2015 Gründemann et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution
License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any
medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://
creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Gründemann et al. BMC Complementary and Alternative Medicine  (2015) 15:219 
DOI 10.1186/s12906-015-0757-6
concentrations available of Colchicum officinale
(Colchicum tuber D3), Mandragora officinale (Mandrag-
ora root D3), Rosmarinus officinale (Rosemary leaves 5 %)
and Kalanchoe pinnata (Bryophyllum leaves 5 %). All
medications have not been investigated in such experi-
ments before.
Colchicum as Colchicine standardized extract is used
for gout treatment in conventional medicine [4]. The al-
kaloid colchicine inhibits mitosis and prevents granulo-
cytes from invading the gout-affected joint. In vitro and
in patients, it has shown to induce lymphocyte and mono-
cyte activation as well as the proliferation of mitogen-
activated lymphocytes [5–7], which resulted in clinical
trials with patients suffering from asthma, liver fibrosis
and others [8–10]. For familial Mediterranean fever,
Behçet's disease and pericarditis with effusion, its efficacy
has been recognized [10]. Colchicum tuber is also used in
AM for treating gout [3].
Indications for Mandragora use in AM are mainly
painful, degenerative and inflammatory disorders of
joints and ligaments. It has been used in folk medicine
as a narcotic, an anesthetic and for the treatment of
various diseases [11, 12] and contains alkaloids with
anticholinergic properties.
Rosemary 5 % is listed in an AM textbook as support-
ive treatment for diabetes [3]. Phenolic compounds from
rosemary and extracts from rosemary exerted in in vitro
studies anti-inflammatory [13, 14] and anti-diabetic [15,
16] properties.
Bryophyllum 5 % is clinically used in AM to improve
restlessness and tension-related symptoms—e.g., in pre-
mature labor [17], but also in patients with diabetes or
hyperthyroidism [3] in order to reduce inflammation.
The extract has shown smooth muscle relaxing proper-
ties [18, 19]. Other extracts from the Bryophyllum family
than Kalanchoe pinnata have shown anti-diabetic activ-
ity [20] and anti-inflammatory effects [21, 22].
Because of the use of drugs from AM in inflamma-
tory disorders and the lack of previous experiments,
we investigated the immunomodulatory potential of a
selection of these preparations in cell-based systems.
Lymphocytes and dendritic cells (DCs) were used as
model systems. As outcome criteria, we determined
lymphocyte viability to see whether it is possible that
the immunomodulatory effects of the extracts are medi-
ated through cytotoxicity and lymphocyte proliferation to
get a hint on immunosuppressive or immunostimulating
properties.
Maturation and function of DCs were analyzed be-
cause DCs play a key role in regulating the immune
function of the body. Their functions are phagocytosis,
antigen recognition and processing, maturation and ini-
tiation of an adaptive immune response by presenting
antigens and activating T cells. As a result, they mediate
between the innate and the adoptive immune system
[23]. Errant DCs are involved in the development of
autoimmune diseases. Maturation of DCs is, amongst
others, indicated by a shift of activation of costimulatory
surface molecules (CD 83, CD 86 and CD 14), which
can be measured by FACS-analyses [24].
Methods
Ethics statement
Patients gave their written consent for giving blood for
scientific research. All experiments conducted on human
material were approved by the ethics committee of the
University of Freiburg (55/14) and conform to the dec-
laration of Helsinki.
Medication
The investigated injectable preparations are officially
registered according to § 38/39 of the German Drug
Law, have marketing authorization in Germany and are
available in the European Union. The extracts from
Colchicum and Mandragora are manufactured according
to methods 21 and 19f respectively of the German
Homeopathic Pharmacopoeia [25]. All specifications for
parental medications were fulfilled according to the
European Pharmacopoeia (EP) [26]. Good Manufactur-
ing Practise (GMP) and quality control according to the
EP is monitored from the German authorities (Federal
Institute for Drugs and Medical Devices; BfArM). This
includes proof of plant source identity and absence of
contamination with heavy metals, pesticides, aflatoxins
and microorganisms. Ampoules from the sales stock
were sent to our laboratory in Freiburg, Germany, where
the cell biological experiments were performed. For each
experiment, a fresh ampoule was used.
Colchicum officinale tuber D3 is manufactured from a
watery extract of the bulb of the flowering meadow saf-
fron. The mother extract is three times diluted 1:10 (D3)
in physiological saline according to the homeopathic
pharmacopoeia. For Mandragora D3, 10 parts of dried
Mandragora root is mixed with 100 parts of ethanol
43 %, mixed and boiled for 30 min. Afterwards, the ex-
tract is pressed and sterile filtered. This mother tincture
is defined as D1. The D3 dilution is prepared by dilution
1:100 with physiological saline. For Rosmarinus 5 %, 10
parts of dried rosemary leaves were mixed with 100
parts of sterile water and were warmed for 5 minutes at
90 °C. The extract was pressed and filtered and was de-
fined as D1 solution. One ampoule (1 mL) contains
0.5 mL of this rosemary extract and 0.5 mL physiological
saline. One ampoule (1 mL) of Bryophyllum 5 % con-
tains 0.1 g of a watery extract from Kalanchoe pinnata
leaves (1:1.1) and physiological saline. All extracts are
manufactured and marketed from Weleda AG
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(Schwäbisch Gmünd, Germany) and sterile filtered
before filling 1 mL ampoules.
Selection of human peripheral lymphocytes and purified
CD4+ T cells
Human peripheral lymphocytes (PBMC) were isolated
from the blood of healthy adult donors obtained from
the Blood Transfusion Centre (University Medical Cen-
ter, Freiburg, Germany). Venous blood was centrifuged on
a LymphoPrepTM gradient (density: 1.077 g/cm3, 20 min,
500 x g, 20 °C; Progen, Heidelberg, Germany). Cells were
washed twice with PBS (Life Technologies, Darmstadt,
Germany), and cell viability as well as cell concentration
were determined using the trypan blue exclusion test.
Purified untouched T cells were obtained by CD4+ nega-
tive selection using the magnetic cell separation method.
Cell suspension of 108/mL was prepared and 100 μL of
the EasySep® Positive Selection Cocktail was added follow-
ing an incubation time of 10 minutes at room
temperature. Afterwards, 50 μL/mL of the magnetic nano-
particles were added, well mixed and incubated at room
temperature. After 5 minutes, the cell suspension was
fixed to a total volume of 2.5 mL by adding recommended
medium. The cells were fixed in the EasySep® magnet for
5 minutes and afterwards the supernatant was discarded
and cell number was determined (all products from Stem-
Cell Technologies, Grenoble, France). Cells were cultured
in RPMI 1640 full media (supplemented with 10 % heat-
inactivated fetal calf serum (PAA, Pasching, Austria),
2 mM L-glutamine, 100 U/mL penicillin and 100 U/mL
streptomycin (all from Life Technologies, Darmstadt,
Germany). The cells were cultured at 37 °C in a humidi-
fied incubator.
Generation and maturation of immature
monocyte-derived DCs
Immature DCs (iDCs) were generated by plastic adher-
ence or CD14-positive selection method. For plastic ad-
herence, isolated PBMC were cultured in RPMI 1640
media (Life Technologies, Darmstadt, Germany) supple-
mented with 2 % human albumin (Albunorm 20 %;
Octapharma, Langenfeld, Germany) at a concentration
of 2x106 cells/cm2 and cultured for adherence of mono-
cytes for 2 hrs at 37 °C in a 5 % CO2/95 % air atmos-
phere. The nonadherent cells were carefully removed by
washing twice with PBS. Purified CD14+ monocytes
were obtained by CD14+ positive selection. Cell suspen-
sion of 108/mL was prepared, and 100 μL of the Easy-
Sep® Positive Selection Cocktail was added following an
incubation time of 10 min at room temperature. After-
wards, 50 μL/mL of the magnetic nanoparticles were
added, well mixed and incubated at room temperature.
After 5 minutes, the cell suspension was fixed to a total
volume of 2.5 mL by adding the recommended medium.
The cells were fixed in the EasySep® magnet for 5 mi-
nutes, and afterwards, the supernatant was discarded
and cell number was determined (all products from
StemCell Technologies, Grenoble, France). For gener-
ation of iDCs, the cells were cultured in serum-free Cell-
Gro DC Media (CellGenix, Freiburg, Germany) added
with 800U/mL recombinant human IL-4 (PeproTech,
Hamburg, Germany) and 1000U/mL recombinant hu-
man GM-CSF (Leukine sargramostim; Bayer, Leverku-
sen, Germany) for 5–6 days at 37 °C in a 5 % CO2/95 %
air atmosphere. For maturation, iDCs were harvested
and were further cultivated at a density of 4x105 cells/
mL for 24–48 hrs in RPMI 1640 full media in the pres-
ence of media or maturation cocktail (500 ng/mL LPS
(Sigma-Aldrich, Taufkirchen, Germany); 50 ng/mL TNF-
alpha and 10 ng/mL IL-1beta (both from PeproTech,
Hamburg, Germany) alone or supplemented with differ-
ent concentrations of anthroposophical test medications
or controls as indicated.
Determination of lymphocyte and DC apoptosis and
necrosis using annexin V and propidium iodide staining
Biological effects of plant-derived extracts on cells are often
mediated through cytotoxicity. Therefore, the levels of
apoptosis and necrosis were determined using the annexin
V-FITC apoptosis/necrosis detection kit (eBioscience,
Frankfurt, Germany). In detail, cells were stained for 15 mi-
nutes at room temperature in the dark with an annexin V
antibody. Afterwards, propidium iodide was added to the
wells, and cells were further incubated for 10 minutes.
After staining, cells were analyzed by flow cytometry to de-
termine the amount of apoptotic and necrotic cells. Posi-
tive controls for apoptosis and necrosis CPT (100 μM) and
Triton-X 100 (0.5 %) were used, respectively. Whole cell
population was gated for analysis.
Cell division tracking of lymphocytes using CFSE staining
PBMC were harvested and washed twice in cold PBS be-
fore they were resuspended in PBS at a concentration of
5 × 106 cells/mL. CFSE (carboxyfluorescein diacetate suc-
cinimidyl ester, 5 mM; Sigma, Taufkirchen, Germany) was
added in 1/1000 dilution, and the PBMC were incubated
for 10 min at 37 °C. The staining reaction was stopped by
washing twice with complete medium. Afterwards, the cell
division progress was analyzed using flow cytometry.
Surface receptor analysis and cytokine determintation of
cendritic cells
The effects of anthroposophical medications on DC mat-
uration were determined by measuring surface receptor
expression (anti-human CD14, CD83 and CD86 mABs;
all from ebioscience, Frankfurt, Germany) using live cell
gating in flow cytometric analysis. IL-10 and IL-12p70
were detected and analyzed in the supernatants of
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cultured cells using classical ELISA technique
(ebioscience, Frankfurt, Germany). The detection levels
were 2 and 4 pg/mL respectively.
Cocultivation of DCs and allogeneic purified T cells
For cocultivation experiments, purified CD4+ T cells (as
described in selection of human peripheral lymphocytes
and purified CD4+ T cells) were harvested and washed
twice in cold PBS and resuspended in PBS at a concentra-
tion of 5x106 cells/mL. Cells were incubated for 10 min at
37 °C with carboxyfluorescein diacetate succinimidyl ester
(CFSE; 5 μM: Sigma-Aldrich, Taufkirchen, Germany). The
staining reaction was stopped by washing twice with
complete RPMI 1640 media. The CFSE+ CD4+ T cells
(5x105) were cultured in 96 U-bottomed plates (Greiner,
Frickenhausen, Germany) with mature DCs (mDCs)
(5x104) that had been matured in the presence or absence
of different concentrations of Rosmarinus officinale 5 %
extract. For analyzing T cell proliferation, the DC:T cell ra-
tio of 1:10 was used, and cells were cultured for 5 days,
followed by flow cytometric analysis. As control, CFSE+
CD4+ T cells were cultured with media alone.
Data analysis
For statistical analysis, data were processed with Micro-
soft Excel and SPSS software (IBM, Version 22.0,
Armonk, USA). Values are presented as mean ± SD for
the indicated number of independent experiments. As a
preliminary point in statistical analysis, normality of data
was confirmed by the Shapiro-Wilk test. Statistical sig-
nificance was determined by one-way ANOVA followed
by Dunnett's post hoc pairwise comparisons or by paired
two-sample t-tests. The asterisks represent significant
differences from the control group (*P < 0.05, **P < 0.01,
***P < 0.001).
Fig. 1 Effects of injectable preparations on apoptosis and necrosis of lymphocytes and DCs. After stimulation of lymphocytes (a) or DCs (b) with
antihuman CD3/28 mAbs (each 10 ng/mL) or TNF-alpha, LPS and IL-1beta, respectively, in the presence of medium, camptothecin (100 μM),
Triton X-100 (0.5 %) or different concentrations of Bryophyllum, Colchicum and Mandragora (all 1:300 (only in A); 1:100; 1:30; 1:10) or Rosmarinus
(1:400 (only in A); 1:200; 1:100; 1:50). The cells were stained with annexin V and propidium iodide (PI) to assess the percentage of apoptotic
(annexin V+/PI−) and (annexin V+/PI+) or necrotic (annexin V−/PI+) cells. The cells were analysed by flow cytometry. The results from two to three
independent experiments are summarized, and data are presented as mean ± standard deviation (SD)
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Results
Injectable preparations of AM have no effect on
apoptosis and necrosis induction of lymphocytes and DCs
We first investigated the effect of four different anthropo-
sophical preparations on apoptosis and necrosis induction
of lymphocytes (Fig. 1a) and DCs (Fig. 1b). In the combined
annexin V/propidium iodide flow cytometric analysis, the
used concentrations of Bryophyllum, Colchicum, Mandrag-
ora and Rosmarinus did not induce apoptosis or necrosis of
lymphocytes or DCs compared to controls.
Injectable Colchicum and Rosmarinus preparation affect
lymphocyte proliferation
We further analysed the impact of different concentra-
tions of Bryophyllum, Colchicum, Mandragora and
Rosmarinus preparations on the cell division of activated
lymphocytes (Fig. 2) and observed that the Bryophyllum
and Mandragora preparations have no impact on the pro-
liferation of lymphocytes. Cells treated with different con-
centrations of Colchicum inhibited the proliferation of
lymphocytes in the used concentration range. Rosmarinus
diminished this parameter only at a high concentration.
Injectable Rosmarinus preparation affects maturation
of DCs
In the next step, we characterized the effects of Bryophyl-
lum, Colchicum, Mandragora and Rosmarinus (Fig. 3) on
expression of typical markers (CD14, CD83 and CD86) as-
sociated with the maturation status of DCs. As shown in
Fig. 3a-d, iDCs express high amounts of CD14 and low
amounts of the surface markers CD83 and CD86. After ac-
tivation with TNF-alpha, LPS and IL-1beta, CD14 was
down-regulated, and the expression of CD83 and CD86
increased on the surface of the cells. The used concentra-
tions of Bryophyllum, Colchicum and Mandragora
(Fig. 3a-c) had no influence on marker expression, but in-
cubation with different concentrations of Rosmarinus
(Fig. 3d) inhibited the maturation of DCs. CD14 expres-
sion increased (0.25 mg/mL: 113 % ± 10; 0.5 mg/mL:
127 % ± 25; 1.0 mg/mL: 157 % ± 58), while CD83 expres-
sion (0.25 mg/mL:: 69 % ± 19; 0.5 mg/mL: 63 % ± 21;
1.0 mg/mL: 61 % ± 24) as well as CD86 expression
(0.25 mg/mL: 86 % ± 12; 0.5 mg/mL: 77 % ± 17; 1.0 mg/mL:
63 % ± 20) decreased compared to mDCs incubated with
media alone (=100 %).
Injectable Rosmarinus preparation modulates cytokine
secretion of DCs
We cultured DCs in the presence of different concentra-
tions of Rosmarinus (1:2000–1:500 corresponding to
0.25- 1 mg/mL) to see whether there is an influence on
IL-10 and IL12p70 secretion of DCs (Fig. 4). iDCs per se
did not secrete IL-10 (Fig. 4a; no detection) and IL-12
(Fig. 4b; 12 % ± 25) in comparison to mDCs (=100 %).
The presence of the Rosmarinus preparation reduced
the release of IL-10 (Fig. 4a) (0.25 mg/mL: 115 % ± 37;
0.5 mg/mL: 99 % ± 40; 1.0 mg/mL: 64 % ± 21) and
IL12p70 (Fig. 4b) (0.25 mg/mL: 115 % ± 30; 0.5 mg/mL:
89 % ± 37; 1.0 mg/mL: 58 % ± 56) which shows that not
only maturation but also the activation status of DCs is
modulated by the Rosmarinus extract.
Injectable Rosmarinus preparation inhibits the
proliferation of allogeneic CD4+ T cells
DCs are an important part of the immune system.
Therefore, we investigated whether DCs that were
Fig. 2 Effects of injectable preparations on proliferation of lymphocytes. CFSE+ lymphocytes were activated with antihuman CD3/28 mAbs (each
10 ng/mL) and were treated with medium, camptothecin (100 μM), Triton X-100 (0.5 %) or different concentrations of Bryophyllum, Colchicum
and Mandragora (all 1:300; 1:100; 1:30; 1:10) or Rosmarinus (1:400; 1:200; 1:100; 1:50) for 72 hrs. After cultivation, the cell division was investigated
using flow cytometric analysis. The results from three independent experiments are summarized, and data are presented as mean ± standard
deviation (SD). The asterisks represent significant differences from untreated, activated lymphocytes alone. n.d. = not detectable (***P < 0.001)
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generated in the presence of the Rosmarinus prepar-
ation influenced the proliferation of allogeneic purified
human lymphocytes (Fig. 5). CD4+ T cells were puri-
fied, labelled with CFSE and were activated with allo-
geneic DCs in the presence of media or different
concentrations (0.25- 1 mg/mL) of the Rosmarinus
preparation. The CFSE dye is inherited by daughter
Fig. 3 Effects of injectable preparations on DC maturation markers.
mDC were cultured in the presence of different concentrations of
Bryophyllum (a; 1:300; 1:100; 1:30), Colchicum (b; 1:300; 1:100; 1:30),
Mandragora (c; 1:100; 1:30; 1:10) or Rosmarinus (d; 1:200; 1:100; 1:50)
for 48 hrs, and marker expression of CD14 (white bars), CD83 (grey
bars) and CD86 (black bars) were detected by using respective mAbs
in flow cytometric analysis. As reference, iDCs were stained with mAbs
in parallel. Results were shown from four to six independent
experiments, and data were presented as mean ± standard deviation
(SD) in relation to mDCs (=100 %). The asterisks represent significant
differences from untreated mDCs alone (*P < 0.05; **P < 0.01)
Fig. 4 Effects of Rosmarinus injectable preparation on cytokine
release of DCs. Secretion of IL-10 (a) and IL-12p70 (b) of iDCs or
mDCs alone or in the presence of different concentrations of
Rosmarinus (0.25-1 mg/mL) were analyzed in the supernatants of
the cells using ELISA-based flow cytometry. Results are summarized
from four to six independent experiments, and data are presented
as mean ± SD. The detection levels were 2 pg/mL (IL-10) and 4 pg/mL
(IL-12) respectively. The asterisks represent significant differences from
untreated mDCs alone (**P < 0.01; paired t-test)
Fig. 5 Effects of Rosmarinus injectable preparation on proliferation
of allogeneic CD4+ T cells. mDCs were cocultured with allogeneic
CFSE-labelled purified human CD4+ T cells (CD4) in the presence of
different concentrations of Rosmarinus (0.25-1 mg/mL) using a DC:T
cell ratio of 10:1 for 5 to 6 days. Cell division analysis was assessed
by flow cytometry and data are presented as mean ± SD of three
independent experiments. The asterisks represent significant
differences from untreated CD4+ T cells alone (*P < 0.05)
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cells after cell division and each dividing cell loses
fluorescent intensity measured by flow cytometry. The
data revealed that allogeneic CD4+ T cells (CD4) prolif-
erate in the presence of mDCs. Furthermore, DCs
which were preincubated with different concentrations
of the Rosmarinus extract inhibited the proliferation of
allogeneic CD4+ T cells only at high concentrations.
Discussion
Preparations from AM have been developed from an hol-
istic view on nature and spiritual science [3] and not from
bench to bedside. Thus, it can be explained that these
preparations are clinically used for the treatment of in-
flammatory disorders but have not yet been tested regard-
ing effects on cells of the human immune system.
Marketing authorisation in Germany and Switzerland
results from history.
Lymphocytes and DCs were used as model systems
because they are important in regulating immunity and
preventing autoimmune diseases. Because we wanted to
evaluate the selected preparations as such, we abstained
from separately testing the effects of known immuno-
modulating compounds in relation to the extracts. Es-
pecially for the Colchicum extract, a relation to a
known immunomodulating compound, namely Colchi-
cine, could be expected. Colchicine inhibits mitosis
and proliferation of immunocompetent cells [5–7] and
was present in the used Colchicum tuber extract in re-
lated doses because Colchicum tuber plant material for
pharmaceutical use is defined to have 0.05–0.4 % Col-
chicine according to German regulations [12]. The in-
hibition of lymphocyte proliferation by the Colchicum
tuber extract used in AM is, therefore, plausible.
Rosmarinus and Bryophyllum are the only parenteral
preparations of AM which are available in the concen-
tration of 5 %. While Bryophyllum 5 % does not affect
the immune response, Rosmarinus 5 % clearly inhib-
ited maturation and functionality of DCs. Because this
effect is not mediated by apoptosis or necrosis, its mo-
lecular mechanism and the clinical implications for the
treatment of diseases with an overactive immune sys-
tem deserve further investigation. The concentrations
used in the in vitro experiment are comparable to the
concentrations which are reached locally after subcuta-
neous injection of one ampoule of the respective prep-
arations. Systemic concentrations in the human body
cannot be estimated because the distribution volume
and the distribution velocity are not known for the
preparations.
Conclusions
Differential effects of the different AM medications on
immune function have been found. Colchicum has
immunosuppressive properties on cell proliferation of
lymphocytes, while Mandragora D3, and Bryophyllum
5 % do not. Rosmarinus officinale 5% additionally inhib-
ited functions of DCs. Clinical relevance and molecular
mechanisms of these findings should be further
evaluated.
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